PL3130353T3 - Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych - Google Patents

Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych

Info

Publication number
PL3130353T3
PL3130353T3 PL15774194T PL15774194T PL3130353T3 PL 3130353 T3 PL3130353 T3 PL 3130353T3 PL 15774194 T PL15774194 T PL 15774194T PL 15774194 T PL15774194 T PL 15774194T PL 3130353 T3 PL3130353 T3 PL 3130353T3
Authority
PL
Poland
Prior art keywords
preventing
pharmaceutical composition
neurodegenerative diseases
treating neurodegenerative
based pharmaceutical
Prior art date
Application number
PL15774194T
Other languages
English (en)
Inventor
Byung Hee Hong
Je Min Yoo
Hanseok Ko
Donghoon Kim
Original Assignee
Seoul National University R&Db Foundation
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&Db Foundation, The Johns Hopkins University filed Critical Seoul National University R&Db Foundation
Publication of PL3130353T3 publication Critical patent/PL3130353T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00Carbon; Compounds thereof
    • C01B32/15Nano-sized carbon materials
    • C01B32/182Graphene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659Radiation therapy using light characterised by the wavelength of light used infrared
    • A61N2005/066Radiation therapy using light characterised by the wavelength of light used infrared far infrared
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/067Radiation therapy using light using laser light
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B2204/00Structure or properties of graphene
    • C01B2204/20Graphene characterized by its properties
    • C01B2204/32Size or surface area

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
PL15774194T 2014-04-04 2015-04-03 Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych PL3130353T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140040400 2014-04-04
PCT/KR2015/003385 WO2015152688A1 (ko) 2014-04-04 2015-04-03 퇴행성 신경 질환의 예방 또는 치료를 위한 그래핀 나노구조체 기반 약학적 조성물
EP15774194.3A EP3130353B1 (en) 2014-04-04 2015-04-03 Graphene nanostructure-based pharmaceutical composition for preventing or treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
PL3130353T3 true PL3130353T3 (pl) 2021-03-08

Family

ID=54240900

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15774194T PL3130353T3 (pl) 2014-04-04 2015-04-03 Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych

Country Status (8)

Country Link
US (2) US20170189359A1 (pl)
EP (1) EP3130353B1 (pl)
JP (1) JP6585156B2 (pl)
KR (1) KR101747147B1 (pl)
CN (2) CN106470706A (pl)
ES (1) ES2814274T3 (pl)
PL (1) PL3130353T3 (pl)
WO (1) WO2015152688A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111542329B (zh) * 2017-11-24 2022-12-13 首尔大学校产学协力团 包含石墨烯纳米结构的抗炎组合物
US20210252051A1 (en) * 2018-07-06 2021-08-19 Biographene Inc. Graphene quantum dot as therapeutic agent for disease associated with abnormal fibrillation or aggregation of neuroprotein
WO2020009551A1 (ko) * 2018-07-06 2020-01-09 바이오그래핀 주식회사 신경단백질의 비정상적 섬유화 또는 응집과 관련된 질환 치료제로서의 그래핀 양자점
EP3597594A1 (en) 2018-07-17 2020-01-22 Graphenano Medical Care, S.L. Graphene product and therapeutic uses thereof
KR102179430B1 (ko) * 2019-01-30 2020-11-16 바이오그래핀 주식회사 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물
CN110251532B (zh) * 2019-07-18 2022-04-15 苏州大学 碳基纳米材料在制备缓解或者治疗hd药物中的应用
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
CN112089731A (zh) * 2020-09-29 2020-12-18 安徽医科大学第一附属医院 纳米氧化石墨烯在β淀粉样蛋白Aβ相关疾病治疗中的应用及其试验方法
CN112552902A (zh) * 2020-11-20 2021-03-26 扬州大学 一种泡沫结构的石墨烯量子点组装体及其制备方法
CN116327934A (zh) * 2023-03-30 2023-06-27 北京理工大学 一种抗β淀粉样蛋白聚集的紫磷@核酸适体纳米片的制备方法和应用
WO2024248251A1 (ko) * 2023-05-30 2024-12-05 그래핀스퀘어케미칼 주식회사 그래핀 양자점을 유효성분으로 포함하는 퇴행성 신경 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063880A1 (en) * 2002-01-29 2003-08-07 Protemix Corporation Limited Disruption of islet amyloid by polycyclic compounds
US7163956B2 (en) * 2003-10-10 2007-01-16 C Sixty Inc. Substituted fullerene compositions and their use as antioxidants
CN101267779A (zh) * 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
GB2432529B (en) 2005-11-25 2008-04-23 Univ Feng Chia Antimicrobial compositions and wound dressings
EP2021352A4 (en) 2006-05-19 2009-10-28 Scripps Research Inst TREATMENT OF POOR FOLDING OF PROTEINS
WO2013066398A1 (en) * 2011-04-26 2013-05-10 William Marsh Rice University Use of carbon nanomaterials with antioxidant properties to treat oxidative stress
US20150050734A1 (en) * 2012-03-27 2015-02-19 Duke University Carbon Nanotubes And Methods Of Use
KR102020870B1 (ko) * 2012-04-30 2019-09-16 바이오그래핀 주식회사 그래핀 양자점 또는 산화그래핀 양자점을 포함하는 mri 조영제, 및 그 제조방법
US10114024B2 (en) 2013-08-28 2018-10-30 Nanyang Technological University Biomolecule-graphene quantum dot conjugates and use thereof
AU2014315289A1 (en) * 2013-09-03 2016-03-17 Baylor College Of Medicine Treatment of inflammatory diseases by carbon materials

Also Published As

Publication number Publication date
EP3130353A4 (en) 2017-11-15
CN113018437A (zh) 2021-06-25
US20170189359A1 (en) 2017-07-06
KR20150115671A (ko) 2015-10-14
CN106470706A (zh) 2017-03-01
ES2814274T3 (es) 2021-03-26
EP3130353B1 (en) 2020-07-22
WO2015152688A1 (ko) 2015-10-08
JP2017510650A (ja) 2017-04-13
US10772910B2 (en) 2020-09-15
US20180289646A1 (en) 2018-10-11
KR101747147B1 (ko) 2017-06-14
EP3130353A1 (en) 2017-02-15
JP6585156B2 (ja) 2019-10-02

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical preparations for combination therapy
IL268316B (en) Pharmaceutical preparations for combined treatment
IL247003A0 (en) Isoindoline compounds and methods for the treatment of neurodegenerative diseases
SG11201705093UA (en) Composition for treating il-6-related diseases
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
PL3130353T3 (pl) Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych
EP3104706A4 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
EP3157631A4 (en) Neurodegenerative disease treatment
ZA201607729B (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
PL3129378T3 (pl) Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
PL3236961T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
ZA201500995B (en) Low dose pharmaceutical composition
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
IL246919A0 (en) New preparations for the treatment of mechanical nerve injuries
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
IL236381A0 (en) Pharmaceutical preparations for the treatment of cancer
HK1232777A1 (en) New compositions for treating mechanical neuronal injuries
HK1236134A1 (en) Pharmaceutical combination for the treatment of cancer
AU2014902366A0 (en) Neurodegenerative disease treatment